Advertisement

Breast Cancer Research and Treatment

, Volume 126, Issue 2, pp 443–451 | Cite as

Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer

  • Norikazu Masuda
  • Hiraji Iwata
  • Yoshiaki Rai
  • Keisei Anan
  • Toru Takeuchi
  • Norio Kohno
  • Hiroyuki Takei
  • Yasuhiro Yanagita
  • Shinzaburo NoguchiEmail author
Clinical trial

Abstract

This study compared the efficacy and safety of a 3-monthly 10.8-mg depot goserelin (ZoladexTM) injection with the current 3.6 mg monthly dose in pre-menopausal Japanese women with estrogen receptor-positive (ER+) early breast cancer. This was a multicenter, open-label, randomized study. Primary endpoint was a non-inferiority analysis (10.8/3.6 mg) of the area under the concentration–time curve (AUC) of estradiol (E2) over the first 24 weeks. Secondary endpoints included E2 and follicle-stimulating hormone (FSH) concentrations, menstruation, and safety and tolerability. In total, 170 patients were randomized to receive goserelin 10.8 mg every 3 months (n = 86) or 3.6 mg every month (n = 84). Mean AUCs for E2 were similar between treatment groups (18.32 and 18.95 pg/ml·week for goserelin 10.8 and 3.6 mg, respectively). AUC ratio was 0.974 (95% confidence interval, 0.80, 1.19), indicating non-inferiority for goserelin 10.8 mg. Serum E2 and FSH remained suppressed throughout the study and no patient experienced menses after week 16. No clinically important differences in safety and tolerability were observed between the two groups. In terms of E2 suppression, 3-monthly goserelin 10.8 mg was non-inferior to monthly goserelin 3.6 mg in pre-menopausal women with ER+ breast cancer.

Keywords

Early breast cancer Goserelin acetate Estrogen suppression Pre-menopausal Zoladex™ 

Notes

Acknowledgments

This work was sponsored by AstraZeneca, who provided support for the conduct of the study, data collection and project management. We thank all the patients and investigators who participated in the study. We also thank Simon Vass, PhD, from Complete Medical Communications who provided medical writing support funded by AstraZeneca. The following investigators (institutions) participated in the study: Seiichi Takenoshita, Tohru Ohtake (Fukushima Medical University Hospital); Yasuo Hozumi (Jichi Medical University Hospital); Jiro Ando (Tochigi Cancer Center); Hidetaka Mochizuki, Kazuhiko Fukatsu (National Defence Medical College Hospital); Kimito Suemasu (Saitama Cancer Center); Takayuki Kinoshita (National Cancer Center Hospital); Seigo Nakamura (St. Luke’s International Hospital); Tsunehiro Nishi (Mitsui Memorial Hospital); Takuji Iwase (The Cancer Institute Hospital of Japanese Foundation for Cancer Research); Shigeru Imoto, Noriaki Wada (National Cancer Center Hospital East); Naohito Yamamoto (Chiba Cancer Center); Yutaka Tokuda (Hospital of the Tokai University School of Medicine); Mamoru Fukuda (St. Marianna University School of Medicine Hospital); Muneaki Sano, Nobuaki Sato (Niigata Cancer Center Hospital); Tetsuya Taguchi (Osaka University Graduate School of Medicine); Hideo Inaji (Osaka Medical Center for Cancer and Cardiovascular Disease); Masahira Watatani (Hospital of Kinki University School of Medicine); Shozo Ohsumi (National Hospital Organization Shikoku Cancer Center); Shinji Ohno (National Hospital Organization Kyusyu Cancer Center); Reiki Nishimura (Kumamoto City Hospital); Hirotaka Iwase (Kumamoto University Hospital); Hidemi Furusawa (Breastopia NAMBA Hospital).

References

  1. 1.
    Debruyne FM, Dijkman GA (1995) Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol 28:177–188PubMedGoogle Scholar
  2. 2.
    Soto AM, Sonnenschein C (1985) The role of estrogens on the proliferation of human breast tumor cells (MCF-7). J Steroid Biochem 23:87–94PubMedCrossRefGoogle Scholar
  3. 3.
    Nicholson S, Halcrow R, Sainsbury J, Angus B, Chambers P, Farndon J, Harris A (1988) Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly postmenopausal patients with breast cancer. Br J Cancer 58:810–814PubMedCrossRefGoogle Scholar
  4. 4.
    AstraZeneca (2009) Zoladex prescribing informationGoogle Scholar
  5. 5.
    AstraZeneca (2009) Zoladex 3.6 mg Implant–Summary of product characteristics (SPC)Google Scholar
  6. 6.
    Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, Robert NJ, Budd GT, Paradelo JC, Natale RB, Bearden JD, Mailliard JA, Osborne CK (1998) Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 16:994–999PubMedGoogle Scholar
  7. 7.
    Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, De Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628–4635PubMedCrossRefGoogle Scholar
  8. 8.
    Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M, Sauerbrei W, Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists’ Group (2003) Survival analyses from the ZEBRA study: goserelin (Zoladex™) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39:1711–1717PubMedCrossRefGoogle Scholar
  9. 9.
    Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn H-J (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 20:1319–1329PubMedCrossRefGoogle Scholar
  10. 10.
    Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92:903–911PubMedCrossRefGoogle Scholar
  11. 11.
    Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R, Combined Hormone Trialists’ Group and the European Organization for Research and Treatment of Cancer (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343–353PubMedGoogle Scholar
  12. 12.
    Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H (2002) Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer–Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621–4627PubMedCrossRefGoogle Scholar
  13. 13.
    Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Sismondi P, Giai M, Genta F, Pacini P, Distante V, Bolognesi A, Aldrighetti D, Farris A (2000) Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 18:2718–2727PubMedGoogle Scholar
  14. 14.
    Dijkman GA, del Moral PF, Plasman JW, Kums JJ, Delaere KP, Debruyne FM, Hutchinson FJ, Furr BJ (1990) A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer. J Steroid Biochem Mol Biol 37:933–936PubMedCrossRefGoogle Scholar
  15. 15.
    Dijkman GA, Debruyne FM, Fernandez del MP, Plasman JW, Hoefakker JW, Idema JG, Sykes M (1994) A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group. Eur Urol 26(Suppl 1):1–2PubMedGoogle Scholar
  16. 16.
    Dijkman GA, Debruyne FM, Fernandez del MP, Plasman JW, Hoefakker JW, Idema JG, Sykes M (1995) A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological Group. Eur Urol 27:43–46PubMedGoogle Scholar
  17. 17.
    Cockshott ID (2000) Clinical pharmacokinetics of goserelin. Clin Pharmacokinet 39:27–48PubMedCrossRefGoogle Scholar
  18. 18.
    Baum M, Hackshaw A, Houghton J, Rutqvist LE, Fornander T, Nordenskjold B, Nicolucci A, Sainsbury R (2006) Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer 42:895–904PubMedCrossRefGoogle Scholar
  19. 19.
    Hackshaw A, Baum M, Fornander T, Nordenskjold B, Nicolucci A, Monson K, Forsyth S, Reczko K, Johansson U, Fohlin H, Valentini M, Sainsbury R (2009) Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 101:341–349PubMedCrossRefGoogle Scholar
  20. 20.
    Nystedt M, Berglund G, Bolund C, Fornander T, Rutqvist LE (2003) Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol 21:1836–1844PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Norikazu Masuda
    • 1
  • Hiraji Iwata
    • 2
  • Yoshiaki Rai
    • 3
  • Keisei Anan
    • 4
  • Toru Takeuchi
    • 5
  • Norio Kohno
    • 6
  • Hiroyuki Takei
    • 7
  • Yasuhiro Yanagita
    • 8
  • Shinzaburo Noguchi
    • 9
    Email author
  1. 1.National Hospital Organization Osaka National HospitalOsakaJapan
  2. 2.Aichi Cancer Center HospitalNagoyaJapan
  3. 3.Sagara HospitalKagoshimaJapan
  4. 4.Kitakyushu Municipal Medical CenterFukuokaJapan
  5. 5.Marumo HospitalNagoyaJapan
  6. 6.Tokyo Medical University HospitalTokyoJapan
  7. 7.Saitama Cancer CenterSaitamaJapan
  8. 8.Gunma Cancer CenterOtaJapan
  9. 9.Department of Breast and Endocrine SurgeryOsaka University Graduate School of MedicineSuitaJapan

Personalised recommendations